NICE gives Aubagio the nod

Share this article:

The UK's price watchdog NICE has approved Sanofi's oral MS medication Aubagio for adults with relapsing-remitting multiple sclerosis, which means the National Health Service will begin funding the drug within the next three months.

Wednesday's thumbs-up is a re-tread. NICE told Sanofi in September that Sanofi had to provide cost-effectiveness data that would indicate the drug deserves a space on the formulary compared to what's already on the market. The drug costs around $22,500 per patient per year in the UK.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions